Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Account Payables: 2014-2025

Historic Change in Account Payables for Aytu Biopharma (AYTU) over the last 6 years, with Sep 2025 value amounting to $1.7 million.

  • Aytu Biopharma's Change in Account Payables fell 44.61% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 1021.49%. This contributed to the annual value of $287,000 for FY2025, which is 113.82% up from last year.
  • Aytu Biopharma's Change in Account Payables amounted to $1.7 million in Q3 2025, which was up 220.90% from -$1.4 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Change in Account Payables registered a high of $6.6 million during Q4 2021, and its lowest value of -$9.9 million during Q3 2021.
  • For the 3-year period, Aytu Biopharma's Change in Account Payables averaged around $285,636, with its median value being $398,000 (2025).
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 375.51% in 2021, then plummeted by 1,174.63% in 2025.
  • Over the past 5 years, Aytu Biopharma's Change in Account Payables (Quarterly) stood at $6.6 million in 2021, then plummeted by 167.24% to -$4.4 million in 2022, then increased by 9.42% to -$4.0 million in 2023, then soared by 54.74% to -$1.8 million in 2024, then crashed by 44.61% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, -$1.4 million for Q2 2025, and $398,000 during Q1 2025.